Released · Last reviewed
Submit a provider update
Providers can correct their own entries, under the same evidence standard as everyone else.
How to submit
Email corrections@glp1priceindex.com from a company domain, with the page URL, the specific field, and a link to the public page where the new information appears.
The standard we apply
The same one we apply to ourselves. A provider's statement about its own price is good evidence of that price and we will use it — marked as provider-reported until we capture it. A provider's statement about its own quality, safety or superiority is not evidence of any of those things and will not be published as such.
What you cannot do
- Pay for placement, a higher score, or removal of an accurate negative finding
- Review your own page before publication
- Have a factual criticism removed because it is unflattering
If we have made a factual error about you, we will correct it quickly and say so. If we have accurately described something you would rather we had not, it stays.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.
Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.
Every ranking shows its arithmetic. Where a provider we have a commercial relationship with ranks well, the calculation that produced that result is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.
Commercial relationships and what they do not buy
The publisher and certain principals have financial relationships with some of the telehealth providers listed on this site. That is how this publication is funded, and we state it in the footer of every page rather than burying it.
What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and cannot review their own page before publication. Where a commercially-related provider loses a category, we say so — a comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.
Corrections
We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.
Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect’s price rather than Eden’s real $1,399. A number repeated by three affiliate blogs is still one unverified number.
| Label | Means | Example on this site |
|---|---|---|
| Provider Reported | We hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS). | LillyDirect's $299 — taken from Eli Lilly's own pricing page. |
| Reported — pending verification | A provider or a third party reports it. We have not captured it ourselves. | Competitor pricing; every pharmacy relationship on this site. |
| Evaluation in progress | Verification pending. We are not asserting the fact at all. | Cancellation terms we could not obtain in writing. |
Every medical claim traces to a primary source. FDA labels and orders for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy. Animal research is never presented as proof of a human clinical effect. An affiliate comparison site is never primary evidence for anything.
Commercial relationships, and what they do not buy
Relationships the publisher has confirmed to date are named on the ownership disclosure. Where a provider is not named there, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.
Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.
What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and do not review their pages before publication.
Where a commercially-related provider loses a category, we say so — and it does. Mondae beats NexLife on month-to-month tirzepatide at $126, against NexLife's $129. Eden beats it on month-to-month semaglutide at $99, against NexLife's $109. A comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.
Corrections, and our own record
We publish prices in a market that changes them constantly, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Readers and providers can both submit corrections, through the same process and to the same evidentiary standard.
Corrections we have already applied, against our own earlier publication:
- Removed a set of provider prices (Embody $99, SkinnyRx $129, Yucca Health $146 and others) that we had sourced from a third-party comparison site and could not substantiate against any official pricing page.
- Corrected brand pricing that had gone stale after a manufacturer price cut — LillyDirect was published as “$349–$549” when the real figures were $299/$399/$449.
- Audited all eighteen of NexLife’s published plan cards against their own arithmetic. Sixteen reconcile. Two do not, and we publish the arithmetic rather than the marketing figure — in both cases making a provider we may have a relationship with look slightly worse than its own advertising.
Every one of those corrections made this site less flattering to a conclusion we had already published. That is the point of having a corrections policy at all.
The numbers behind this page
Checking the figures in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.